The global transcatheter heart valve replacement market enjoys a valuation of US$ 5.7 Billion in 2022, and it is further projected to expand at a CAGR of 14.8% over the forecasted years. According to a recent study by Future Market Insights, balloon-expandable transcatheter aortic valves are leading the market with a share of about 52.5% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 5.7 Billion |
| Market Value 2033 | US$ 25.4 Billion |
| CAGR 2023 to 2033 | 14.8% |
| Market Share of Top 5 Countries | 79.5% |
| Key Market Players | Abbott; Edwards Lifesciences Corporation; Medtronic; Boston Scientific Corporation; JenaValve Technology, Inc.; Meril Life Sciences; Sahajanand Medical Technologies Limited MicroPort Scientific Corporation; Venus Medtech (Hangzhou) Inc.; Suzhou Jiecheng Medical Technology Co. Ltd.; Peijia Medical Limited; and Blue Sail Medical Co., Ltd. |
Transcatheter heart valve replacement is also known as percutaneous aortic valve replacement (PAVR). It is a less invasive procedure to replace the damaged aortic valve with a bioprosthetic aortic valve. This procedure is performed to treat patients suffering from severe aortic stenosis (aortic stenosis), valve-in-valve procedures (failed bioprosthesis), and aortic regurgitation that restricts blood flow from the ventricle to the aorta caused by the building up of calcium on the valve. A transcatheter aortic valve is designed for patients for whom conventional open-heart surgery is not a safe option.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 14.8% between 2023 and 2033, owing to the rising prevalence of various cardiovascular diseases.
The global market holds around 40.2% share of the overall global cardiac surgery market with a value of around US$ 14.2 Billion, in 2022.
One of the key factors propelling growth of the market in the coming years is the surge in the demand for minimally invasive procedures due to the various benefits offered by these surgeries.
Several published studies in recent times have concluded that the second-generation TAVR devices have better safety-related benefits. These studies also conclude that transcatheter heart valve devices are linked with a lower rate of paravalvular regurgitation, valve embolization and other bleeding events. The advancement in technologies is quite trendy in the dynamic field of transcatheter aortic valve implantation (TAVI). This aspect will support the expansion of the market for transcatheter heart valve replacement.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 25.4 billion during the year 2033.
The market is anticipated to expand due to ongoing clinical research in TAVR innovations, creating a huge opportunity for the market players to step into the market.
At the forefront of cardiovascular care, cardiovascular experts who treat some of the most complex heart conditions by using the latest technology and landmark research, including transcatheter aortic valve replacement (TAVR), lead several comprehensive programs. TAVR is a new, rapidly developing therapy, which offers patients the best possible TAVR technology.
In order to keep a running clinical research programme that gives patients access to advanced technologies, several research groups are participating. TAVR valves with a smaller diameter, valves with better sealing, and valves that may be moved for more accurate placement are a few examples of more recent, experimental technologies.
Numerous heart patients will benefit from TAVR as a treatment for heart valve disease owed to the market opportunities being created by the market players due to the rapid speed of clinical research in TAVR Innovations.
Principal Consultant
The market is expected to grow owed to the rising number of procedures and FDA approvals. However, some factors limit the market.
The high cost that is linked to transcatheter aortic valves is one of the key restraining factors for the TAVR market. Price is a crucial factor, which decides whether the device is feasible to be bought. Since the prices associated with such valves are quite high, therefore this is considered a restraining factor for this market.
Although TAVR is considered an alternative to the open-heart aortic valve replacement procedure, there are some complications related to this kind of procedure. These potential risks include complications in the blood vessels, stroke, problems related to the rhythm of the heart, heart attack, infection, serious bleeding, problems related to the positioning of the valve like valve slipping out of place or regurgitation and others.
The USA dominates the North American region with a total market share of around 91.4% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
As per the findings from the American College of Cardiology, the prevalence of valvular heart diseases is quite high in reference to the American population. It reports that there are more than 5 million Americans who are diagnosed with such diseases in a year. This number includes 1.5 million individuals who suffer from aortic stenosis in the USA and the ones who suffer from severe aortic stenosis comprise around 500,000 individuals, this is around 33% of the cases suffering from aortic stenosis.
Since the primary treatment for severe aortic stenosis is valve replacement surgery, therefore this factor influences the TAVR market in the most favourable manner in the USA market.
Germany holds a market share of 33.9% in 2022 in the European transcatheter heart valve replacement market, owing to the presence of many established players and a maximum number of TAVI procedures among European countries. According to an article, 'Valve for Life': tackling the deficit in transcatheter treatment of heart valve disease in the UK - published in Open Heart in March 2021, 292 TAVI procedures per million population (PMP) were conducted in 2019 in Germany. According to a review by Cardiac Interventions Today, TAVR has become increasingly popular throughout Europe and is currently the most widely used method for treating aortic stenosis in older people ever since the feasibility and early safety of the procedure were evaluated and significant technical concerns were resolved.
India holds a share of around 44.3% in the South Asia market in 2022. Both rheumatic and non-rheumatic aortic stenosis are currently overrepresented in India. Despite the fact that TAVR has altered the treatment of non-rheumatic aortic stenosis, there is reason to be optimistic about the future of rheumatic aortic stenosis. Due to the enormous demand and limited resources, the device and pharmaceutical sectors collaborated with the government to disseminate TAVR across the Indian subcontinent. They can also assist in the training of medical professionals, raising awareness among the general public and medical experts, and researching and developing novel valves that are tailored to the specific needs of the Indian population.
China has a market share of 51.8%, with a market value of US$ 87.2 Million in the East Asia transcatheter heart valve replacement market in 2022.
As China's infrastructure matures and offers more device alternatives due to technological advancements, access to transcatheter aortic valve replacement (TAVR) procedures will increase quickly. To support the predicted rise of TAVR, domestic companies specialising in devices for structural heart disorders are also expanding quickly.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Self–expandable transcatheter aortic valves are expected to give high growth at a CAGR of 16.0% between 2023 and 2033. Self-expandable valves (SEVs) have a better hemodynamic profile with a lower mean gradient and a higher effective orifice area at discharge and at 1-year follow-up. The supra-annular design of SEVs can lessen the danger of significant transvalvular gradients by reducing the impact of valve asymmetry and under-expansion. These factors promote product adoption globally.
TAVR procedures are mostly preferred for patients suffering from severe aortic valve stenosis. It has a market share of 76.7% in the global market in 2022.
Chest pain, shortness of breath, fainting, and weariness are some of the indications and symptoms of aortic valve stenosis that can be lessened with TAVR. For those who run the risk of problems from surgical aortic valve replacement, TAVR may be an option. The heart valve can be replaced to treat severe AS, a condition that poses a life-threatening risk. Aortic valve replacement is the main form of treatment for severe AS, thus promoting market expansion.
Hospitals hold a market share of 53.6% during the year 2022. Hospitals are the primary places where complicated and technologically advanced surgical procedures are undertaken. TAVR is normally carried out in a hospital by cardiologists, or physicians who specialise in cardiac surgeries. The medical professionals will measure the valve opening before TAVR, after which they will give patients sedatives or tranquillizers as well as medications to stop potentially fatal blood clots. Owed to comprehensive care within the hospital settings, the segment is set to expand at a lucrative rate over the forecast period.
Increasing products in the pipeline and approval by the regulatory bodies, expansion in other regions, and marketing approvals in different regions, are key differentiating strategies that TAVR manufacturers are adopting. The market's dynamics have changed due to increased awareness.
Instances of important developmental strategies used among market participants in the transcatheter heart valve replacement market are presented below:
Similarly, recent developments related to companies manufacturing transcatheter heart valve replacement products have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2016 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries and South Africa |
| Key Market Segments Covered | Product, Indication, End User, and Region |
| Key Companies Profiled | Abbott; Edwards Lifesciences Corporation; Medtronic; Boston Scientific Corporation; JenaValve Technology, Inc; Meril Life Sciences; Sahajanand Medical Technologies Limited; MicroPort Scientific Corporation; Venus Medtech (Hangzhou) Inc.; Suzhou Jiecheng Medical Technology Co. Ltd.; Peijia Medical Limited.; Blue Sail Medical Co., Ltd. |
| Pricing | Available upon Request |
The global transcatheter heart valve replacement (TAVR) market is worth US$ 5.7 Billion for 2022, and is set to expand 4.0X over the next ten years.
The global market is estimated to reach US$ 6.4 Billion in 2023.
The market is expected to reach US$ 25.4 Billion by end of 2033.
The market exhibited a value CAGR of 8.9% in the last 6 years.
market is projected to grow at a CAGR of 14.8% between 2023 and 2033.
Self–expandable transcatheter aortic valves by product segment will garner a significant share of 47.9% in 2023.
Severe aortic valve stenosis by indication segment is predicted to expand rapidly with a CAGR of 15.1% between 2023 and 2033.
1. Executive Summary | Transcatheter Heart Valve Replacement Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Key Success Factors 4.1. TAVI procedure Adoption Pattern Analysis 4.2. Disease Epidemiology 4.3. Regulatory Landscape 4.4. PESTLE Analysis 4.5. Porter’s Analysis 4.6. Product USPs/Features 4.7. Reimbursement Scenario 4.8. TAVR Procedures Per Year 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.1.3. Global Life Expectancy Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. Market Consolidation Activities 5.2.3. New Product Launches / Approvals 5.2.4. Rising demand for Transcatheter Heart Valve Replacement 5.2.5. Availability of Products 5.2.6. Cost of Products 5.2.7. Growing Investment in Healthcare Expenditure 5.2.8. Regulatory Scenario 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. COVID-19 Crisis – Impact Assessment 6.1. Impact of COVID-19: An Overview 6.2. COVID-19 and Impact Analysis 6.2.1. By Product 6.2.2. By Indication 6.2.3. By End User 6.2.4. By Region 6.3. 2022 Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2016 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2016 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Product, 2016 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033 8.3.1. Self–Expandable Transcatheter Aortic Valves 8.3.2. Balloon-Expandable Transcatheter Aortic Valves 8.3.3. Mechanically Expanded Transcatheter Aortic Valves 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By Indication, 2016 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 9.3.1. Severe Aortic Valve Stenosis 9.3.2. Valve-in-Valve Procedures (Failed Bioprosthesis) 9.3.3. Aortic Regurgitation 9.4. Market Attractiveness Analysis By Indication 10. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By End User, 2016 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 10.3.1. Hospitals 10.3.2. Independent Cardiac Catheterization Labs 10.3.3. Ambulatory Surgical Centres 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2016 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2016 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Product 12.3.3. By Indication 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Product 12.4.3. By Indication 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Product 12.8.1.2.2. By Indication 12.8.1.2.3. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Product 12.8.2.2.2. By Indication 12.8.2.2.3. By End User 13. Latin America Transcatheter Heart Valve Replacement Market Analysis 2016 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Product 13.3.3. By Indication 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product 13.4.3. By Indication 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Product 13.8.1.2.2. By Indication 13.8.1.2.3. By End User 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Product 13.8.2.2.2. By Indication 13.8.2.2.3. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Product 13.8.3.2.2. By Indication 13.8.3.2.3. By End User 14. Europe Market Analysis 2016 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. UK 14.3.1.2. Germany 14.3.1.3. France 14.3.1.4. Italy 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Product 14.3.3. By Indication 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Indication 14.4.4. By End User 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. UK Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Product 14.7.1.2.2. By Indication 14.7.1.2.3. By End User 14.7.2. Germany Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Product 14.7.2.2.2. By Indication 14.7.2.2.3. By End User 14.7.3. France Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Product 14.7.3.2.2. By Indication 14.7.3.2.3. By End User 14.7.4. Italy Market Analysis 14.7.4.1. Introduction 14.7.4.2. Market Analysis and Forecast by Market Taxonomy 14.7.4.2.1. By Product 14.7.4.2.2. By Indication 14.7.4.2.3. By End User 14.7.5. Spain Market Analysis 14.7.5.1. Introduction 14.7.5.2. Market Analysis and Forecast by Market Taxonomy 14.7.5.2.1. By Product 14.7.5.2.2. By Indication 14.7.5.2.3. By End User 14.7.6. BENELUX Market Analysis 14.7.6.1. Introduction 14.7.6.2. Market Analysis and Forecast by Market Taxonomy 14.7.6.2.1. By Product 14.7.6.2.2. By Indication 14.7.6.2.3. By End User 14.7.7. Russia Market Analysis 14.7.7.1. Introduction 14.7.7.2. Market Analysis and Forecast by Market Taxonomy 14.7.7.2.1. By Product 14.7.7.2.2. By Indication 14.7.7.2.3. By End User 15. East Asia Market Analysis 2016 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Product 15.3.3. By Indication 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Indication 15.4.4. By End User 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. China Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Product 15.7.1.2.2. By Indication 15.7.1.2.3. By End User 15.7.2. Japan Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Product 15.7.2.2.2. By Indication 15.7.2.2.3. By End User 15.7.3. South Korea Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Product 15.7.3.2.2. By Indication 15.7.3.2.3. By End User 16. South Asia Market Analysis 2016 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Malaysia 16.3.1.3. Thailand 16.3.1.4. Indonesia 16.3.1.5. Rest of South Asia 16.3.2. By Product 16.3.3. By Indication 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Indication 16.4.4. By End User 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Product 16.7.1.2.2. By Indication 16.7.1.2.3. By End User 16.7.2. Malaysia Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Product 16.7.2.2.2. By Indication 16.7.2.2.3. By End User 16.7.3. Thailand Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Product 16.7.3.2.2. By Indication 16.7.3.2.3. By End User 16.7.4. Indonesia Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Product 16.7.4.2.2. By Indication 16.7.4.2.3. By End User 17. Oceania Market 2016 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Product 17.3.3. By Indication 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Indication 17.4.4. By End User 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. Australia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Product 17.7.1.2.2. By Indication 17.7.1.2.3. By End User 17.7.2. New Zealand Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Product 17.7.2.2.2. By Indication 17.7.2.2.3. By End User 18. Middle East and Africa (MEA) Market Analysis 2016 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2016 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. By Product 18.3.3. By Indication 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Indication 18.4.4. By End User 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. GCC Countries Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Product 18.7.1.2.2. By Indication 18.7.1.2.3. By End User 18.7.2. Türkiye Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Product 18.7.2.2.2. By Indication 18.7.2.2.3. By End User 18.7.3. South Africa Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Product 18.7.3.2.2. By Indication 18.7.3.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players (%) 19.3. Market Presence Analysis 19.3.1. By Regional Footprint of Players 19.3.2. Product Footprint of Players 19.3.3. Channel Footprint of Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Abbott 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Key Financials 20.3.1.4. SWOT Analysis 20.3.1.5. Key Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.2. Edwards Lifesciences Corporation 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Key Financials 20.3.2.4. SWOT Analysis 20.3.2.5. Key Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.3. Medtronic 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Key Financials 20.3.3.4. SWOT Analysis 20.3.3.5. Key Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.4. Boston Scientific Corporation 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Key Financials 20.3.4.4. SWOT Analysis 20.3.4.5. Key Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.5. JenaValve Technology, Inc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Key Financials 20.3.5.4. SWOT Analysis 20.3.5.5. Key Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.6. Meril Life Sciences 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Key Financials 20.3.6.4. SWOT Analysis 20.3.6.5. Key Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.7. Sahajanand Medical Technologies Limited 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Key Financials 20.3.7.4. SWOT Analysis 20.3.7.5. Key Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.8. MicroPort Scientific Corporation 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Key Financials 20.3.8.4. SWOT Analysis 20.3.8.5. Key Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.9. Venus Medtech (Hangzhou) Inc. 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Key Financials 20.3.9.4. SWOT Analysis 20.3.9.5. Key Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.10. Suzhou Jiecheng Medical Technology Co. Ltd. 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Key Financials 20.3.10.4. SWOT Analysis 20.3.10.5. Key Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.11. Peijia Medical Limited. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Key Financials 20.3.11.4. SWOT Analysis 20.3.11.5. Key Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.12. Blue Sail Medical Co., Ltd. 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Key Financials 20.3.12.4. SWOT Analysis 20.3.12.5. Key Developments 20.3.12.6. Sales Footprint 20.3.12.7. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Transcatheter Heart Valve Replacement Market
